TNXP

Over the past six months (approximately April to October 2026), Tonix Pharmaceuticals Holding Corp. (TNXP) stock experienced a significant decline, decreasing by 41.40% in the past month and 43.0% over the last six months, reaching $7.70 per share as of October 6, 2026, a 66.54% drop from a year prior. Key events included commercial payer agreements for TONMYA in May, July, and September 2026, providing access to approximately 35 million U.S. commercial lives and expected to cover 46% of Americans by January 2027, which led to shares trading higher. Financial results for Q1 2026 showed 2,145 healthcare providers prescribing TONMYA, 3,588 patients initiating treatment, and approximately 5,400 prescriptions filled, with net sales rising from $3.7 million in Q1 to $11 million in Q2 2026, and approximately $185.5 million in cash and cash equivalents as of March 31, 2026. Pipeline advancements included the enrollment of the first patient in the Phase 2 HORIZON study for TNX-102 SL in MDD in June 2026 and positive FDA meeting minutes for a Phase 2 field study of TNX-4800 for Lyme disease prevention in August 2026. Leadership changes saw Thomas Englese promoted to Chief Commercial Officer in September 2026. Some analysts initiated bullish coverage on TNXP, though the stock's Momentum Indicator turned negative and the 10-day moving average crossed bearishly below the 50-day moving average in September 2026, indicating a potential downward trend.